RecruitingNCT06402981
A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver Injury in Lung Cancer Patients
Sponsor
Zhejiang University
Enrollment
2,000 participants
Start Date
Jan 1, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to investigate the risk factors of PD-1/PD-L1 inhibitor-associated liver injury, to construct a prediction model for the occurrence of liver injury. The main questions it aims to answer are: * Exploring risk factors for liver injury. * Constructing a Predictive Model for the Occurrence of Liver Injury in PD-1/PD-L1 Inhibitor-Related Liver Injury. * Improving immunotherapy protocols for lung cancer patients.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria2
- Lung cancer patients who have received at least one and more PD-1/PD-L1 inhibitor treatments;
- Gender is not limited, age 18-80 years old
Exclusion Criteria2
- Severe liver injury prior to immunotherapy (elevation of transaminases, alkaline phosphatase, and glutamyl aminotransferase more than 5 times the upper limit of normal).
- Patients who, in the opinion of the investigator, are not suitable for participation in the study.
Interventions
OTHERHigh risk prediction model for liver injury
Risk Prediction Model for Liver Injury After Use of PD-1/PD-L1 Inhibitors
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06402981